The company’s stock fell by more than 40 percent Friday after the approval of Lyfgenia, the release of its pricing, and comparison to a less expensive gene-edited drug approved the same day.
The Food and Drug Administration is expected to approve a new gene editing therapy for sickle cell disease, its first green light for a Crispr treatment.
The US FDA approved the first gene editing therapy to treat patients with sickle cell disease - a crippling condition that leaves sufferers in life-altering pain.
/PRNewswire/ Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will.